Eckhart Weidmann
Frankfurt Am Main, HE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
Journal: Leukemia & lymphoma
Published: November 24, 2015
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Journal: The Lancet. Oncology
Published: September 03, 2015
A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 23, 2014
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Journal: British journal of haematology
Published: July 16, 2014
Long-term complete remission following radiosurgery and immunotherapy in a melanoma patient with brain metastasis: immunologic correlates.
Journal: Cancer immunology research
Published: May 06, 2014
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Journal: Cancer treatment reviews
Published: August 21, 2013
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 20, 2013
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Journal: Lancet (London, England)
Published: February 26, 2013
Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 25, 2011
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
Journal: Leukemia & lymphoma
Published: February 10, 2010
Showing 1-10 of 10
Last Updated: 09/26/2026